---
title: "CareDx Upgraded on Strong MolDx Reimbursement Decision as Massaro Lifts Price Target from $28 to $45"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292935517.md"
description: "BTIG analyst Mark Massaro upgraded CareDx to Buy, raising the price target from $28 to $45. This decision follows a favorable MolDx reimbursement policy that ensures broad coverage for kidney, heart, and lung transplant tests with higher testing frequencies than initially proposed. The improved policy removes regulatory overhangs and supports potential volume expansion, leading Massaro to increase valuation multiples based on stronger long-term revenue expectations."
datetime: "2026-07-16T17:25:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292935517.md)
  - [en](https://longbridge.com/en/news/292935517.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292935517.md)
generator: "portal-rs"
---

# CareDx Upgraded on Strong MolDx Reimbursement Decision as Massaro Lifts Price Target from $28 to $45

Analyst Mark Massaro of BTIG reiterated a Buy rating on CareDx, boosting the price target to $45.00.

Mark Massaro has given his Buy rating due to a combination of factors tied to a materially better-than-expected final coverage decision for CareDx’s transplant tests and the resulting upside to future revenue expectations. The finalized MolDx policy maintains broad reimbursement for kidney, heart, and lung surveillance with higher allowable testing frequencies than initially proposed, preserves the HeartCare combination offering, and removes a key regulatory overhang that had constrained investor interest.

Massaro also sees meaningful room for test volume expansion across all three organs, as current clinical usage sits below the newly affirmed limits, supporting potential upside to Street estimates for 2026–2028. In addition, he highlights an improved risk-reward profile and raises his price target from $28 to $45 by applying a higher valuation multiple to longer-term revenue, reflecting increased confidence in CareDx’s growth trajectory and durability of its reimbursement framework.

### Related Stocks

- [CDNA.US](https://longbridge.com/en/quote/CDNA.US.md)

## Related News & Research

- [CareDx (CDNA) Rallies On Transplant Growth Narrative But Is The Valuation Still Compelling](https://longbridge.com/en/news/298232920.md)
- [171,014 Shares in CareDx, Inc. $CDNA Bought by Bank of New York Mellon Corp](https://longbridge.com/en/news/298099350.md)
- [VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook](https://longbridge.com/en/news/298508921.md)
- [MAZE: Promising phase II results and novel mechanisms drive kidney and PKU drug development, with pivotal trials ahead](https://longbridge.com/en/news/298635059.md)
- [OSE Immunotherapeutics says first patient dosed in Phase 2 RENGEVITY-201 trial of VEL-101 in kidney transplant rejection prevention](https://longbridge.com/en/news/298482622.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**